Red Abbey Venture Partners
10751 Falls Rd Ste 300, Lutherville Timonium, MD, 21093, United States
Overview
Red Abbey Venture Partners is a life sciences investment firm that was founded in 2004. Since that time, it has invested in 15 privately held and 9 publicly traded life sciences companies. Mission is to generate superior, risk-adjusted returns by investing in young companies that are developing the next generation of drugs and devices, as well as companies that are supporting these efforts with novel tools and products. Specifically, seeking to invest across the life sciences spectrum, which includes biotechnology, specialty pharmaceutical, medical device, diagnostics and research tools companies.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- Anacor Pharmaceutical
Participated · Equity · Jan 2009
Anacor Pharmaceuticals is a Palo Alto-based biopharmaceutical company developing small-molecule therapeutics derived from its boron chemistry platform. The company has discovered and is developing five clinical compounds, including lead programs AN2690 (a topical antifungal for onychomycosis), AN2728 (a topical anti-inflammatory PDE-4 inhibitor for psoriasis) and GSK 2251052 (a systemic antibiotic optioned to GlaxoSmithKline). Additional candidates include AN2718 (topical antifungal) and AN2898 (topical anti-inflammatory for psoriasis and atopic dermatitis). Anacor is privately held; investors include Rho Ventures, Venrock Associates, Care Capital Investments and Aberdare Ventures. Financially, Anacor was awarded approximately $1.5M from the U.S. Department of the Treasury under the Qualifying Therapeutic Discovery Project Program, with $1.4M payable in November 2010 and $0.1M in the first quarter of 2011. The grant is part of a federal program under the Patient Protection and Affordable Care Act to support research aimed at producing new therapies for unmet medical needs. Anacor Pharmaceuticals develops topical treatments for fungal infections of the nails. The company is based in Palo Alto, Calif. Its lead program is a topical antifungal aimed at onychomycosis and is being advanced toward phase three clinical trials. Anacor has partnerships with GlaxoSmithKline and Schering‑Plough, both of which became stockholders. Financially, the company recently raised $50 million in a fifth round, bringing total capital raised to $87 million. It previously raised $5 million in a fourth round in 2006 and withdrew an IPO filing two weeks earlier due to poor market conditions.
Team
No current team members are available.